BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38515096)

  • 1. Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases.
    Qi H; Hou Y; Zheng Z; Zheng M; Qiao Q; Wang Z; Sun X; Xing L
    BMC Cancer; 2024 Mar; 24(1):362. PubMed ID: 38515096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MRI radiomics predicts the efficacy of EGFR-TKI in EGFR-mutant non-small-cell lung cancer with brain metastasis.
    Qi H; Hou Y; Zheng Z; Zheng M; Sun X; Xing L
    Clin Radiol; 2024 Jul; 79(7):515-525. PubMed ID: 38637187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.
    Qu J; Zhang T; Zhang X; Zhang W; Li Y; Gong Q; Yao L; Lui S
    Clin Radiol; 2024 Apr; 79(4):e582-e591. PubMed ID: 38310058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiparametric MRI-Based Radiomics Approaches for Preoperative Prediction of EGFR Mutation Status in Spinal Bone Metastases in Patients with Lung Adenocarcinoma.
    Jiang X; Ren M; Shuang X; Yang H; Shi D; Lai Q; Dong Y
    J Magn Reson Imaging; 2021 Aug; 54(2):497-507. PubMed ID: 33638577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiregional radiomics of brain metastasis can predict response to EGFR-TKI in metastatic NSCLC.
    Fan Y; Wang X; Dong Y; Cui E; Wang H; Sun X; Su J; Luo Y; Yu T; Jiang X
    Eur Radiol; 2023 Nov; 33(11):7902-7912. PubMed ID: 37142868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinguishing EGFR mutation molecular subtypes based on MRI radiomics features of lung adenocarcinoma brain metastases.
    Xu J; Yang Y; Gao Z; Song T; Ma Y; Yu X; Shi C
    Clin Neurol Neurosurg; 2024 May; 240():108258. PubMed ID: 38552362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MRI-based radiomics analysis for predicting the EGFR mutation based on thoracic spinal metastases in lung adenocarcinoma patients.
    Ren M; Yang H; Lai Q; Shi D; Liu G; Shuang X; Su J; Xie L; Dong Y; Jiang X
    Med Phys; 2021 Sep; 48(9):5142-5151. PubMed ID: 34318502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MRI-Based Radiomics Nomogram as a Potential Biomarker to Predict the EGFR Mutations in Exon 19 and 21 Based on Thoracic Spinal Metastases in Lung Adenocarcinoma.
    Cao R; Dong Y; Wang X; Ren M; Wang X; Zhao N; Yu T; Zhang L; Luo Y; Cui EN; Jiang X
    Acad Radiol; 2022 Mar; 29(3):e9-e17. PubMed ID: 34332860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brain-Tumor Interface-Based MRI Radiomics Models to Determine EGFR Mutation, Response to EGFR-TKI and T790M Resistance Mutation in Non-Small Cell Lung Carcinoma Brain Metastasis.
    Fan Y; Wang X; Yang C; Chen H; Wang H; Wang X; Hou S; Wang L; Luo Y; Sha X; Yang H; Yu T; Jiang X
    J Magn Reson Imaging; 2023 Dec; 58(6):1838-1847. PubMed ID: 37144750
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Can CT Radiomics Detect Acquired T790M Mutation and Predict Prognosis in Advanced Lung Adenocarcinoma With Progression After First- or Second-Generation EGFR TKIs?
    Yang X; Fang C; Li C; Gong M; Yi X; Lin H; Li K; Yu X
    Front Oncol; 2022; 12():904983. PubMed ID: 35875167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development and externally validate MRI-based nomogram to assess EGFR and T790M mutations in patients with metastatic lung adenocarcinoma.
    Fan Y; Dong Y; Wang H; Wang H; Sun X; Wang X; Zhao P; Luo Y; Jiang X
    Eur Radiol; 2022 Oct; 32(10):6739-6751. PubMed ID: 35729427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved survival and intracranial tumor control of EGFR-mutated NSCLC patients with newly developed brain metastases following stereotactic radiosurgery and EGFR-TKI: a large retrospective cohort study and meta-analyses.
    Kuan AS; Chiang CL; Wu HM; Yang HC; Chen CJ; Lin CJ; Guo WY; Pan DH; Chung WY; Lee CC
    J Neurooncol; 2023 Sep; 164(3):729-739. PubMed ID: 37721662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study.
    Liu Y; Wang J; Wu J; Yang Q; Zeng Y; Wu D; Tian C; Hu Y; Gu F; Li C; Zhang K; Liu L
    Technol Cancer Res Treat; 2021; 20():1533033821997819. PubMed ID: 33715525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases.
    Ke SB; Qiu H; Chen JM; Shi W; Chen YS
    Curr Med Sci; 2018 Dec; 38(6):1062-1068. PubMed ID: 30536070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinically practical radiomics-clinical combined model based on PET/CT data and nomogram predicts EGFR mutation in lung adenocarcinoma.
    Chang C; Zhou S; Yu H; Zhao W; Ge Y; Duan S; Wang R; Qian X; Lei B; Wang L; Liu L; Ruan M; Yan H; Sun X; Xie W
    Eur Radiol; 2021 Aug; 31(8):6259-6268. PubMed ID: 33544167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic analysis and risk stratification of lung adenocarcinoma undergoing EGFR-TKI therapy with time-serial CT-based radiomics signature.
    Zhang X; Lu B; Yang X; Lan D; Lin S; Zhou Z; Li K; Deng D; Peng P; Zeng Z; Long L
    Eur Radiol; 2023 Feb; 33(2):825-835. PubMed ID: 36166088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peritumoural MRI radiomics signature of brain metastases can predict epidermal growth factor receptor mutation status in lung adenocarcinoma.
    Huang Z; Tu X; Yu T; Zhan Z; Lin Q; Huang X
    Clin Radiol; 2024 Feb; 79(2):e305-e316. PubMed ID: 38000953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.
    Chen Y; Yang J; Li X; Hao D; Wu X; Yang Y; He C; Wang W; Wang J
    Cancer Sci; 2016 Dec; 107(12):1800-1805. PubMed ID: 27627582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiomics for lung adenocarcinoma manifesting as pure ground-glass nodules: invasive prediction.
    Sun Y; Li C; Jin L; Gao P; Zhao W; Ma W; Tan M; Wu W; Duan S; Shan Y; Li M
    Eur Radiol; 2020 Jul; 30(7):3650-3659. PubMed ID: 32162003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.
    Chen Y; Wei J; Cai J; Liu A
    BMC Cancer; 2019 Aug; 19(1):793. PubMed ID: 31399067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.